SLXN Receives Israeli MoH Approval for Phase 2/3 SIL204 Trial in Pancreatic Cancer, KRAS-Targeted RNAi Therapy, Preclinical Anti-Tumor Activity Demonstrated, Plans 2026 Initiation, EU Submissions Planned
Silexion Therapeutics Corp Ordinary Shares · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $4.98
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS